Clinical efficacy and safety of ambrocol oral liquid combined with pidotimod oral liquid in allergic asthma in children with mite / 中国生化药物杂志

Objective To investigate the clinical curative effect and safety of ambrocol oral liquid combined with pidotimod oral liquid in the treatment of children with mite allergic asthma.Methods 54 cases of children with mite allergic asthma from December 2014 to December 2015 were selected and randomly divided into the control group and experimental group,27 cases in each group.On the basis of routine treatment,the control group was given pidotimod oral solution 10mL,once a day,oral; on the basis of the control group,the experimental group was treated with ambrocol oral solution 10mL,twice a day,oral.Interleukin-2(IL-2),interleukin-4(IL-4),immunoglobulin E(IgE)levels,the efficacy and safety of the two groups were measured before and after treatment.Results After treatment,compared with the control group,the serum levels of IL-2 were higher,and the levels of IL-4、IgE were lower in the experimental group,the difference was statistically significant(P<0.05),the treatment efficiency of the experimental group(92.59％)was significantly higher than that of the control group(81.48％),the difference was statistically significant(P<0.05).Conclusion The ambrocol oral liquid combined with pidotimod oral liquid can significantly improve the serum level of IL-2,and reduce the serum level of IL-4,IgE in children with mite allergic asthma,improve clinical efficacy.

Effect of ipratropium bromide on serum IL-13, TGF-β1 and VEGF in children with asthma / 中国生化药物杂志

Objective To explore the effect of ipratropium bromide on serum interleukin-13 (IL-13), transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in children with asthma.Methods Eighty-six children with asthma in pediatrics department of Hanggang Hospital from January 2014 to June 2014 were selected and divided into two groups according to different therapy, 43 cases in each group.Control group received aminophylline of intravenous drip infusion and salbutamol and ketotifen orally.Experimental group received ipratropium bromide of aerosol inhalation on the basis of control group, twice daily and treated for two courses, 7 days of one course.The clinical efficacy , serum IL-13, TGF-β1, VEGF and lung function post-treatment were compared between two groups.Results The total curative effect of experimental group was 90.69%, which was significantly higher than 72.09% of control group(χ2 =4.91,P<0.05).The serum levels of IL-13, TGF-β1 and VEGF after 3, 7 and 14 days’ treatment in two groups were lower than those pre-treatment(P<0.05).The above indicators of experimental group were lower than those of control group at the same time point(P<0.05).The FEV1 and FEV1/FVC% after 7, 14 days’ treatment in control group and the above indicators after 3, 7, 14 days’ treatment in experimental group were significantly higher than those pre-treatment (P<0.05).The above indicators of experimental group were higher than those of control group at the same time point (P<0.05).Conclusion Ipratropium bromide could affect serum IL-13, TGF-β1 and VEGF levels in children with asthma, improve lung function and clinical curative effect.